Modina (Nimodipine)

Nimodipine blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This reduces calcium entry, causing selective relaxation of those vessels, which increases cerebral blood flow and counteracts the narrowing (vasospasm) that can follow a subarachnoid bleed.

The dosing regimen for Modina is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals adjust the infusion rate or volume to achieve the therapeutic goal while monitoring safety parameters.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Modina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Nimodipine is distinguished by its high lipophilicity and preferential cerebral vasodilation, whereas other agents such as nicardipine affect systemic vessels more broadly. This makes nimodipine particularly suited for neurovascular indications, while alternatives may be chosen for general hypertension or peripheral vascular disease.

Modina should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze the solution, and ensure the container remains sealed until use.

Modina is supplied as a sterile solution for intracisternal or intravenous injection. Administration is performed by qualified healthcare professionals in a controlled setting, with dosing adjusted according to the patient’s clinical status and continuous monitoring of vital signs.

The most serious adverse events include severe hypotension, myocardial infarction, cardiac arrhythmias, hepatic dysfunction, and rare anaphylactic reactions. Prompt recognition and management of these conditions are essential, and treatment should be discontinued if they occur.

Modina is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation, as well as in individuals with severe hypotension or uncontrolled cardiac failure. Caution is also advised for patients with significant liver impairment.